Jeffrey Lee named chief medical executive at MD Anderson

In the era of immunotherapy, response rate alone fails to predict true patient benefit
Regulators must adapt

March is National Colorectal Cancer Awareness Month. It is a reminder of a heartbreaking trend that oncologists like me are witnessing in our clinics: Last year, for the first time, colorectal cancer became the leading cause of cancer-related death in Americans under the age of 50, according to data published earlier this year in JAMA.

March 27, 2026

Vol.52 No.12

By Richard M. Goldberg

Beyond the lab: Engineering collaboration in modern cancer research

Cancer research increasingly demands environments that mirror the biology it seeks to understand: Complex, adaptive and deeply interconnected. At Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine, collaboration is not treated as an optional cultural trait but as a structural requirement.

March 27, 2026

Vol.52 No.12

Clinical Roundup

Combination treatment benefits patients with leptomeningeal metastases from breast cancer, MD Anderson study finds

Patients with leptomeningeal metastasis have historically had few treatment options. Now, researchers from The University of Texas MD Anderson Cancer Center have found a combination of targeted therapies, tucatinib and trastuzumab, plus the chemotherapy drug, capecitabine, may improve symptoms and extend survival in some breast cancer patients with LM.

March 27, 2026

Vol.52 No.12

Clinical Roundup

Dual-targeting approach improves immunotherapy response in glioblastoma, MD Anderson study finds

Researchers from The University of Texas MD Anderson Cancer Center have found that simultaneously blocking two key “don’t eat me” signals found in cancer cells heightens the immune response and sensitizes tumors to immunotherapy in models of glioblastoma, highlighting a promising strategy.

March 27, 2026

Vol.52 No.12

NCI

A new working group will conduct site visits and advise NCAB and NCI director on cancer center grants

The National Cancer Advisory Board has established an ad hoc working group that will assess cancer centers as part of the designation process. The decision was approved unanimously with one abstention at the NCAB meeting March 17.

Computational model measures key aging metric from routine biopsies, Sanford Burnham study finds

A computational tool infers changes occurring at the ends of the chromosomes housing our DNA, which it does so by detecting structural alterations in cells and tissues captured in images taken of routine medical biopsies, according to a study by scientists at Sanford Burnham Prebys Medical Discovery Institute.

March 20, 2026

Vol.52 No.11

Jeffrey Lee named chief medical executive at MD Anderson

YOU MAY BE INTERESTED IN

In the era of immunotherapy, response rate alone fails to predict true patient benefit
Regulators must adapt

Beyond the lab: Engineering collaboration in modern cancer research

Combination treatment benefits patients with leptomeningeal metastases from breast cancer, MD Anderson study finds

Dual-targeting approach improves immunotherapy response in glioblastoma, MD Anderson study finds

A new working group will conduct site visits and advise NCAB and NCI director on cancer center grants

Computational model measures key aging metric from routine biopsies, Sanford Burnham study finds

Renew today!

Subscriber content

Never miss an issue!

Login

Jeffrey Lee named chief medical executive at MD Anderson

YOU MAY BE INTERESTED IN

In the era of immunotherapy, response rate alone fails to predict true patient benefitRegulators must adapt

Beyond the lab: Engineering collaboration in modern cancer research

Combination treatment benefits patients with leptomeningeal metastases from breast cancer, MD Anderson study finds

Dual-targeting approach improves immunotherapy response in glioblastoma, MD Anderson study finds

A new working group will conduct site visits and advise NCAB and NCI director on cancer center grants

Computational model measures key aging metric from routine biopsies, Sanford Burnham study finds

Never miss an issue!

Login

In the era of immunotherapy, response rate alone fails to predict true patient benefit
Regulators must adapt